Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study

Rutger Verbeek, S. Matthijs Boekholdt, Robert M. Stoekenbroek, G. Kees Hovingh, Joseph L. Witztum, Nicholas J. Wareham, Manjinder S. Sandhu, Kay‐Tee Khaw, Sotirios Tsimikas

Journal of Lipid Research · 2016 · 39 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

Variable agreement exists between different lipoprotein (a) [Lp(a)] measurement methods, but their clinical relevance remains unclear. The predictive value of Lp(a) measured by two different assays [Randox and University of California, San Diego (UCSD)] was determined in 623 coronary artery disease (CAD) cases and 948 controls in a case-control study within the EPIC-Norfolk Prospective Population Study. Participants were divided into sex-specific quintiles, and by Lp(a) <50 versus ∼50 mg/dl, which represents the 80th percentile in northern European subjects. Randox and UCSD Lp(a) levels were strongly correlated; Spearman's correlation coefficients for men, women, and sexes combined were 0.905, 0.915, and 0.909, respectively (P < 0.001 for each). The >80th percentile cutoff values, however, were 36 mg/dl and 24 mg/dl for the Randox and UCSD assays, respectively. Despite this, Lp(a) levels were significantly associated with CAD risk, with odds ratios of 2.18 (1.58–3.01) and 2.35 (1.70–3.26) for people in the top versus bottom Lp(a) quintile for the Randox and UCSD assays, respectively. This study demonstrates that CAD risk is present at lower Lp(a) levels than the currently suggested optimal Lp(a) level of <50 mg/dl. Appropriate thresholds may need to be population and assay specific until Lp(a) assays are standardized and Lp(a) thresholds are evaluated broadly across all populations at risk for CVD and aortic stenosis. Variable agreement exists between different lipoprotein (a) [Lp(a)] measurement methods, but their clinical relevance remains unclear. The predictive value of Lp(a) measured by two different assays [Randox and University of California, San Diego (UCSD)] was determined in 623 coronary artery disease (CAD) cases and 948 controls in a case-control study within the EPIC-Norfolk Prospective Population Study. Participants were divided into sex-specific quintiles, and by Lp(a) <50 versus ∼50 mg/dl, which represents the 80th percentile in northern European subjects. Randox and UCSD Lp(a) levels were strongly correlated; Spearman's correlation coefficients for men, women, and sexes combined were 0.905, 0.915, and 0.909, respectively (P < 0.001 for each). The >80th percentile cutoff values, however, were 36 mg/dl and 24 mg/dl for the Randox and UCSD assays, respectively. Despite this, Lp(a) levels were significantly associated with CAD risk, with odds ratios of 2.18 (1.58–3.01) and 2.35 (1.70–3.26) for people in the top versus bottom Lp(a) quintile for the Randox and UCSD assays, respectively. This study demonstrates that CAD risk is present at lower Lp(a) levels than the currently suggested optimal Lp(a) level of <50 mg/dl. Appropriate thresholds may need to be population and assay specific until Lp(a) assays are standardized and Lp(a) thresholds are evaluated broadly across all populations at risk for CVD and aortic stenosis. Elevated levels of lipoprotein (a) [Lp(a)] are a genetic, independent risk factor for the development of CVD (1Erqou S. Kaptoge S. Perry P.L. Di Angelantonio E. Thompson A. White I.R. Marcovina S.M. Collins R. Thompson S.G. Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.J. Am. Med. Assoc. 2009; 302: 412-423Crossref PubMed Scopus (1145) Google Scholar). The European Atherosclerosis Society (EAS) Consensus Panel has recommended that Lp(a) levels should be measured in patients with an intermediate or high CVD risk and that desirable Lp(a) levels are below the 80th percentile of the population distribution, which roughly corresponded to 50 mg/dl in a Copenhagen population of 6,000 subjects (2Nordestgaard B.G. Chapman M.J. Ray K. Boren J. Andreotti F. Watts G.F. Ginsberg H. Amarenco P. Catapano A. Descamps O.S. et al.European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status.Eur. Heart J. 2010; 31: 2844-2853Crossref PubMed Scopus (1246) Google Scholar). Precise and reliable measurement methods are therefore essential to guide clinical decision making. Yet, previous studies have indicated substantial differences in Lp(a) values as measured by various assays and among different racial groups (3Marcovina S.M. Albers J.J. Scanu A.M. Kennedy H. Giaculli F. Berg K. Couderc R. Dati F. Rifai N. Sakurabayashi I. et al.Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).Clin. Chem. 2000; 46: 1956-1967Crossref PubMed Scopus (223) Google Scholar, 4Lamon-Fava S. Marcovina S.M. Albers J.J. Kennedy H. Deluca C. White C.C. Cupples L.A. McNamara J.R. Seman L.J. Bongard V. et al.Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.J. Lipid Res. 2011; 52: 1181-1187Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar). An important limitation in the inconsistency of measurements is the fact that many assays are affected by the size of apo(a), the major protein component of Lp(a), and that antibodies and calibrators vary across platforms. Based on genetic variants of this protein, large interindividual differences in apo(a) isoform size exist. Previous studies have attempted to elucidate the clinical relevance of the poor interassay agreement in terms of cardiovascular risk classification. Marcovina et al. (3Marcovina S.M. Albers J.J. Scanu A.M. Kennedy H. Giaculli F. Berg K. Couderc R. Dati F. Rifai N. Sakurabayashi I. et al.Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).Clin. Chem. 2000; 46: 1956-1967Crossref PubMed Scopus (223) Google Scholar) assessed the concordance in Lp(a) results among 22 different Lp(a) assays. Considerable heterogeneity was observed, in particular between apo(a) size-sensitive assays. The authors also speculated that this inaccuracy might translate into inaccurate risk assessment. A direct comparison of three Lp(a) assays in a subset of the Framingham Offspring cohort demonstrated large interassay differences in Lp(a) values and consequently in the 80th percentile cutoff values, which was largely determined by differences in apo(a) isoform size (4Lamon-Fava S. Marcovina S.M. Albers J.J. Kennedy H. Deluca C. White C.C. Cupples L.A. McNamara J.R. Seman L.J. Bongard V. et al.Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.J. Lipid Res. 2011; 52: 1181-1187Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar). However, the number of coronary artery disease (CAD) events in that study was limited. A recent meta-analysis evaluated the CVD predictive value between pooled isoform-sensitive and isoform-insensitive assays (5Erqou S. Thompson A. Di Angelantonio E. Saleheen D. Kaptoge S. Marcovina S. Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.J. Am. Coll. Cardiol. 2010; 55: 2160-2167Crossref PubMed Scopus (245) Google Scholar) and observed a substantial heterogeneity between the different studies. However, no formal assay comparisons were made, and assays were performed in different study populations, making it impossible to directly compare the predictive value of different assays. Understanding appropriate assay and population thresholds for risk are essential as novel therapies, including antisense oligonucleotides, proprotein convertase subtilisin kexin type 9 inhibitors and cholesteryl ester transfer protein inhibitors, and mipomersen (6Tsimikas S. Viney N.J. Hughes S.G. Singleton W. Graham M. Baker B.F. Burkey J.L. Yang Q. Marcovina S.M. Geary R.S. et al.Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study..Lancet. 2015; 386: 1472-1483Abstract Full Text Full Text PDF PubMed Scopus (339) Google Scholar, 7Gaudet D. Kereiakes D.J. McKenney J.M. Roth E.M. Hanotin C. Gipe D. Du Y. Ferrand A.C. Ginsberg H.N. Stein of a proprotein convertase 9 on pooled of two phase J. Cardiol. Full Text Full Text PDF PubMed Scopus Google Scholar, M.J. H. D. M. R. S.M. et in with a pooled of than patients in phase Am. Coll. Cardiol. PubMed Scopus Google Scholar, S. M. A.M. M. P. et the and of in patients with or at high risk for coronary heart J. Med. 2010; PubMed Scopus Google Scholar, Catapano J.L. E. S. an antisense to in various populations with results of phase 2015; PubMed Scopus Google lower were to the population thresholds suggested for optimal levels broadly to groups of patients to the concordance between a and Lp(a) assay with a in CAD this in a case-control study in the European Prospective of Prospective Population Study. The EPIC-Norfolk Prospective Population has in N. S. R. S. A. N. study and of the European Prospective of J. Google Scholar). the EPIC-Norfolk Prospective Population and between and and in The study was to the of and on the risk of and were to study of Participants were and were subjects have for at the of with for the all for study were their number by with the which all and for the of or to the of the International of CAD was as with the as to CAD was as with the as to this specific the of a case-control study by et al. S.M. R. N.J. factor and the risk of or to coronary artery disease in or the EPIC-Norfolk Prospective Population J. Med. Full Text Full Text PDF PubMed Scopus Google Scholar). were as a were at and or with CAD as the were as study were at and CVD the study attempted to two controls to by and of this study Lp(a) levels were measured in at the University of California, San Diego as S. J.J. N.J. J. A. J.L. et and risk of and coronary Am. Coll. Cardiol. 2010; PubMed Scopus Google Scholar). it was to Lp(a) levels in the EPIC-Norfolk cohort at the University of on as D. S. C. N.J. S.M. et al.Lipoprotein(a) and risk of and artery disease: the EPIC-Norfolk Prospective Population PubMed Scopus Google Scholar). the case-control to however, all were measured with assays. the current is on the between two of Lp(a) the study was study as N. S. R. S. A. N. study and of the European Prospective of J. Google Scholar). and were determined with the The was for the of in Lp(a) levels were determined in that at the Randox Lp(a) levels were determined on a with an D. S. C. N.J. S.M. et al.Lipoprotein(a) and risk of and artery disease: the EPIC-Norfolk Prospective Population PubMed Scopus Google Scholar). This assay Lp(a) as a and calibrators and controls plasma by The Lp(a) is isoform by of the to of type but the assay is isoform independent by the This assay assays, to apo(a) and Lp(a) apo(a) to it is as than the UCSD and at Lp(a) levels were also determined with an Lp(a) assay by et al. S. A. J.L. coronary results in in and and to PubMed Scopus Google which the with a S. J.J. N.J. J. A. J.L. et and risk of and coronary Am. Coll. Cardiol. 2010; PubMed Scopus Google Scholar). is a to apo(a) that was by with the apo(a) This is present as on and of apo(a) and with This assay is also a assay as it a to and apo(a) with apo(a) is with this but it is present to in in This assay has high and a to mg/dl. This assay to mg/dl to a of values, plasma The values to the calibrators were by the and This assay with Lp(a) assays, has a of of and has in than studies and patients S. J.J. N.J. J. A. J.L. et and risk of and coronary Am. Coll. Cardiol. 2010; PubMed Scopus Google Scholar, A. J.L. S. on a cardiovascular disease and cardiovascular Med. 2011; PubMed Scopus Google Scholar, S. J.L. M. plasma levels of and present on in patients with coronary in the PubMed Scopus Google Scholar, P. S. F. J.L. P. M. Q. A. J. S. and of cardiovascular risk with in the Study.J. Am. Coll. Cardiol. PubMed Scopus Google Scholar, C. H. M. S. Yang J.L. et of of on (a) and lipoprotein Lipid Res. Full Text Full Text PDF PubMed Scopus Google Scholar). The current is on of Lp(a) measurements in the cohort The of cases and controls is therefore on the between Lp(a) measurements performed in a case-control as and the EPIC-Norfolk of this the by and was were for cases and controls by The correlation between Lp(a) levels as measured by the Randox and UCSD assays was correlation the Consensus Panel recommended the 80th percentile as the cutoff value for an Lp(a) level (2Nordestgaard B.G. Chapman M.J. Ray K. Boren J. Andreotti F. Watts G.F. Ginsberg H. Amarenco P. Catapano A. Descamps O.S. et al.European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status.Eur. Heart J. 2010; 31: 2844-2853Crossref PubMed Scopus (1246) Google performed sex-specific and pooled Lp(a) the 80th percentile in populations is to roughly to an Lp(a) level of 50 mg/dl, also performed in which were the Lp(a) of 50 mg/dl. the between Lp(a) levels and the risk of were performed to the odds ratios and Lp(a) the quintile as reference odds ratios were determined for with Lp(a) levels mg/dl, <50 mg/dl as reference were performed for and sex-specific and also for and combined pooled assessed the concordance between the assays in study as <50 mg/dl versus mg/dl. were performed with A of study Lp(a) measurements by the Randox and UCSD assays. This 623 CAD cases and 948 are in cases levels of and and were to and have with Lp(a) levels measured by the Randox assay were mg/dl for mg/dl for mg/dl for and mg/dl for Lp(a) levels measured by the UCSD assay were mg/dl for mg/dl for mg/dl for and mg/dl for Randox UCSD are as for with a distribution, for with a distribution, and number for in a are as for with a distribution, for with a distribution, and number for Lp(a) levels as by the Randox and UCSD assays were strongly Spearman's correlation coefficients for men, women, and sexes combined were 0.905, 0.915, and 0.909, respectively (P < 0.001 for each). The differences in Lp(a) levels measured by the Randox and UCSD assays were in the quintiles, with the Randox assay Lp(a) levels than the UCSD as in and The 80th percentile thresholds were also The Randox assay 80th percentile values of mg/dl, mg/dl, and 36 mg/dl for men, women, and sexes respectively. The 80th percentile thresholds to the UCSD assay were mg/dl, mg/dl, and 24 mg/dl for men, women, and sexes respectively. with assays, the 80th percentile thresholds were below 50 mg/dl. the Randox the of cases versus controls among the pooled sexes in the quintile to in the the UCSD assay the were in the quintile and in the the mg/dl, the of cases versus controls were for the Randox assay and for the UCSD of coronary heart disease cases and controls by Lp(a) UCSD of of of are as number or the and sex-specific were the pooled were Lp(a) for quintile the cutoff in a of cases and controls by Lp(a) Randox of of of are as number or the and sex-specific were the pooled were Lp(a) for quintile the cutoff in a are as number or the and sex-specific were the pooled were Lp(a) for quintile the cutoff are as number or the and sex-specific were the pooled were Lp(a) for quintile the cutoff ratios for the risk of CAD by Lp(a) quintiles, as as for the comparison mg/dl versus <50 mg/dl, are in and ratios for people in the top quintile >80th with in the quintile were 2.18 the Randox assay and 2.35 the UCSD ratios for people with Lp(a) mg/dl versus <50 mg/dl were for the Randox assay and for the UCSD ratios for risk by Lp(a) are as odds ratios with the and women, odds ratios were with the Lp(a) cutoff values as in the and odds ratios were with the Lp(a) cutoff values as in ratios quintile with the quintile as reference an odds is for people with Lp(a) mg/dl, with Lp(a) <50 mg/dl as reference in a are as odds ratios with the and women, odds ratios were with the Lp(a) cutoff values as in the and odds ratios were with the Lp(a) cutoff values as in ratios quintile with the quintile as reference an odds is for people with Lp(a) mg/dl, with Lp(a) <50 mg/dl as reference The between the two assays in study to an Lp(a) level or below 50 mg/dl is in A of study results for assays. results were observed in study of with Lp(a) <50 mg/dl on the Randox assay but Lp(a) mg/dl on the UCSD Lp(a) mg/dl on the Randox assay but Lp(a) <50 mg/dl on the UCSD of study with an Lp(a) level <50 mg/dl and mg/dl are as in a are as A was performed to the level of agreement between the UCSD and the Randox assays The was mg/dl, the lower of agreement was mg/dl, and the of agreement was mg/dl. the level of agreement was but with the level of agreement This study evaluated population and assay thresholds for the predictive value of Lp(a) for the risk of CAD with two different assays measured in the subjects. predictive value for subjects with or CAD was but this was in the of the population for the assay in terms of but Lp(a) levels and 80th percentile cutoff for assays, the 80th percentile were significantly lower than 50 mg/dl, the proposed which was on the Copenhagen Population (2Nordestgaard B.G. Chapman M.J. Ray K. Boren J. Andreotti F. Watts G.F. Ginsberg H. Amarenco P. Catapano A. Descamps O.S. et al.European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status.Eur. Heart J. 2010; 31: 2844-2853Crossref PubMed Scopus (1246) Google Scholar, M. A. B.G. levels and risk of in the the Copenhagen Heart PubMed Scopus Google Scholar, A. B.G. levels and cardiovascular risk Am. Coll. Cardiol. PubMed Scopus Google Scholar). This was on of Lp(a) values in the population and on risk of Lp(a) and genetic studies the risk thresholds at mg/dl in populations (1Erqou S. Kaptoge S. Perry P.L. Di Angelantonio E. Thompson A. White I.R. Marcovina S.M. Collins R. Thompson S.G. Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.J. Am. Med. Assoc. 2009; 302: 412-423Crossref PubMed Scopus (1145) Google Scholar, D. S. C. N.J. S.M. et al.Lipoprotein(a) and risk of and artery disease: the EPIC-Norfolk Prospective Population PubMed Scopus Google Scholar, M. A. B.G. levels and risk of in the the Copenhagen Heart PubMed Scopus Google but mg/dl in populations that have with as and J.J. A. P. Marcovina S.M. of and and to cardiovascular the in with and on Am. Coll. Cardiol. PubMed Scopus (223) Google Scholar, A.M. J. M. White S. concentration coronary and cardiovascular events in patients with coronary heart PubMed Scopus Google Scholar). that the thresholds for is a high level and is at risk should be as thresholds until assays all are standardized and assay the values for a plasma a of and calibrators should be on and across all assay platforms. Lp(a) of an in which is to of in which the number of is the of apo(a) isoform to C. (a) lipoprotein (a) and concentration in PubMed Scopus Google Scholar, S.M. Albers J.J. between number of and of isoforms in for a standardized isoform Chem. PubMed Scopus Google Scholar). The number of is with the plasma level of Lp(a) and of plasma Lp(a) levels M. A. B.G. levels and risk of in the the Copenhagen Heart PubMed Scopus Google Scholar, R. A. S. S. S. et variants associated with Lp(a) lipoprotein level and coronary J. Med. 2009; PubMed Scopus Google Scholar). genetic of are present in the and and that high or Lp(a) levels D. J. J.J. et in the of is associated with coronary artery PubMed Scopus Google Scholar, D. J.J. J.J. in the plasma cardiovascular disease, and 2009; Full Text Full Text PDF PubMed Scopus Google Scholar, E. C.C. J. C. Apolipoprotein(a) for than of the in plasma PubMed Scopus Google Scholar, F. by Med. PubMed Scopus Google Scholar, J. M. Lipoprotein(a) for Full Text Full Text PDF PubMed Scopus Google Scholar). of Lp(a) to the of for clinical Lp(a) measurement methods are on a of including and S.M. Albers J.J. of the number of on measurements of lipoprotein(a).Clin. Chem. PubMed Scopus Google Scholar). to protein assays, Lp(a) assays are of the large in size and of the apo(a) protein size, which is by the heterogeneity in the number of has two that for two apo(a) in than 40 isoforms of apo(a) have and of have two apo(a) isoforms in plasma E. C.C. J. C. Apolipoprotein(a) for than of the in plasma PubMed Scopus Google Scholar). the of is differences of may in of Lp(a), as the on apo(a) and the of the which may the of Lp(a) levels by S.M. Albers J.J. S. of the and on and cardiovascular disease: recent and Chem. PubMed Scopus Google Scholar). that and are the of different antibodies the of and all methods which by isoform of antibodies that to different on apo(a) are the it is that a of of antibodies be at The as by of to is the Lipid and that to is also important to that assays than all antibodies to antibodies should be to the of isoform the of isoform has to by of it is that of antibodies have isoform the of appropriate pooled plasma many to of pooled high Lp(a) plasma but also be of plasma that have values to is important that the calibrators the of the of between and within and that are present in the A of pooled plasma for calibrators is that to the of and and may be a is This important as the measurement of Lp(a) is to with to lower levels and the measurement of Lp(a) levels calibrators should be to the reference material the to isoform the limitation of interassay many the of apo(a) assays with Lp(a) the has to the concentration of Lp(a) as number in the reference of the International Federation of Clinical Chemistry as a to the to in Lp(a) S.M. Albers J.J. S. of the and on and cardiovascular disease: recent and Chem. PubMed Scopus Google Scholar, F. J.R. Marcovina S.M. A. International Federation of Clinical Chemistry and Laboratory Medicine for Lipoprotein(a) reference for for Lp(a) Chem. Med. PubMed Scopus Google Scholar). This with an Lp(a) concentration of and a and apo(a) measurement of the of Lp(a) (3Marcovina S.M. Albers J.J. Scanu A.M. Kennedy H. Giaculli F. Berg K. Couderc R. Dati F. Rifai N. Sakurabayashi I. et al.Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).Clin. Chem. 2000; 46: 1956-1967Crossref PubMed Scopus (223) Google Scholar). roughly to with a of in this is appropriate and should be as it on the isoform as as a concentration of the and of the Lp(a), which are Marcovina S. of 2010; Full Text Full Text PDF PubMed Scopus Google Scholar). the of with in appropriate calibrators the need of pooled plasma the to assays, clinical decision and clinical with have in the EPIC-Norfolk high Lp(a) levels were strongly associated with an risk of CAD S. J.J. N.J. J. A. J.L. et and risk of and coronary Am. Coll. Cardiol. 2010; PubMed Scopus Google Scholar, D. S. C. N.J. S.M. et al.Lipoprotein(a) and risk of and artery disease: the EPIC-Norfolk Prospective Population PubMed Scopus Google Scholar). are with the and studies and a correlation between Lp(a) levels and risk of CVD (2Nordestgaard B.G. Chapman M.J. Ray K. Boren J. Andreotti F. Watts G.F. Ginsberg H. Amarenco P. Catapano A. Descamps O.S. et al.European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status.Eur. Heart J. 2010; 31: 2844-2853Crossref PubMed Scopus (1246) Google Scholar, S. Thompson A. Di Angelantonio E. Saleheen D. Kaptoge S. Marcovina S. Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.J. Am. Coll. Cardiol. 2010; 55: 2160-2167Crossref PubMed Scopus (245) Google Scholar, S. J.J. N.J. J. A. J.L. et and risk of and coronary Am. Coll. Cardiol. 2010; PubMed Scopus Google Scholar). the current independent of the type of assay or the of the study Lp(a) levels in of 50 mg/dl or the quintile 80th were with CAD The 80th percentile cutoff values, in a population in CAD of 36 mg/dl for the Randox assay and 24 mg/dl for the UCSD assay were lower than the proposed of 50 mg/dl but are with and (2Nordestgaard B.G. Chapman M.J. Ray K. Boren J. Andreotti F. Watts G.F. Ginsberg H. Amarenco P. Catapano A. Descamps O.S. et al.European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status.Eur. Heart J. 2010; 31: 2844-2853Crossref PubMed Scopus (1246) Google Scholar, S. Thompson A. Di Angelantonio E. Saleheen D. Kaptoge S. Marcovina S. Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.J. Am. Coll. Cardiol. 2010; 55: 2160-2167Crossref PubMed Scopus (245) Google Scholar, M. A. B.G. levels and risk of in the the Copenhagen Heart PubMed Scopus Google Scholar, A. B.G. levels and cardiovascular risk Am. Coll. Cardiol. PubMed Scopus Google Scholar). This is clinical decision making is suggested to be on the 50 mg/dl in mg/dl as risk P. E. Lp(a) and the risk for Full Text PDF PubMed Scopus Google Scholar). by studies at the level M. A. B.G. levels and risk of in the the Copenhagen Heart PubMed Scopus Google that CVD risk associated with Lp(a) at lower levels than 50 mg/dl. to specific thresholds is to 80th percentile this the of interassay is assay has cutoff this to it is to Lp(a) levels of a of than a on and it be a it was in the study that levels of Lp(a) may also need to be to differences in the thresholds and predictive values for across W. J. Stein R. et is a in cutoff values for coronary heart disease risk the of 2015; PubMed Scopus Google Scholar). However, this was by a number of cardiovascular events and in the a need for of as as clinical with novel (6Tsimikas S. Viney N.J. Hughes S.G. Singleton W. Graham M. Baker B.F. Burkey J.L. Yang Q. Marcovina S.M. Geary R.S. et al.Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study..Lancet. 2015; 386: 1472-1483Abstract Full Text Full Text PDF PubMed Scopus (339) Google Scholar, 7Gaudet D. Kereiakes D.J. McKenney J.M. Roth E.M. Hanotin C. Gipe D. Du Y. Ferrand A.C. Ginsberg H.N. Stein of a proprotein convertase 9 on pooled of two phase J. Cardiol. Full Text Full Text PDF PubMed Scopus Google Scholar, M.J. H. D. M. R. S.M. et in with a pooled of than patients in phase Am. Coll. Cardiol. PubMed Scopus Google Scholar, S. M. A.M. M. P. et the and of in patients with or at high risk for coronary heart J. Med. 2010; PubMed Scopus Google Scholar, Catapano J.L. E. S. an antisense to in various populations with results of phase 2015; PubMed Scopus Google have to into the appropriate risk is to the that Lp(a) CVD of this study are that it which was and also two assays. studies a of assays in populations be to results that lower cutoff values of Lp(a) be and the of different assays have large on clinical decision making. the of to lower Lp(a) to levels, of assay be to clinical decision making for the people with Lp(a) levels S. Lipoprotein(a) as a genetic risk factor of cardiovascular disease: a for to and Am. Coll. Cardiol. PubMed Scopus Google Scholar). The authors to the and of the EPIC-Norfolk Prospective Population Study. coronary artery disease coronary heart disease European Atherosclerosis Society European Prospective of type lipoprotein (a) University of California, San Diego

References

33